Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | TKT | P29401 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10397830 | 0.81 | SCN9A (0.52) | SCN9ASCN2ASCN3ASCN10AKDM4E | |
| SCHEMBL10200326 | 0.80 | KDM4E (0.46) | SCN9ASCN2ASCN3ASCN10AKDM4E | |
| SCHEMBL16631609 | 0.79 | KDM4E (0.45) | SCN9ASCN2ASCN3ASCN10AKDM4E | |
| SCHEMBL31438597 | 0.79 | KDM4E (0.45) | SCN9ASCN2ASCN3ASCN10AKDM4E | |
| SCHEMBL18153016 | 0.79 | PTK2 (0.50) | SCN9ASCN2ASCN3ASCN10AKDM4E | |
| SCHEMBL31438491 | 0.79 | PTK2 (0.50) | SCN9ASCN2ASCN3ASCN10AKDM4E | |
| SCHEMBL1721734 | 0.76 | MAPK8 (0.45) | SCN9ASCN2ASCN3ASCN10AKDM4E | |
| SCHEMBL2019170 | 0.73 | KDM4E (0.46) | SCN9ASCN2ASCN3ASCN10AKDM4E | |
| SCHEMBL263287 | 0.73 | SCN10A (0.60) | SCN9ASCN2ASCN3ASCN10AALDH1A1 | |
| SCHEMBL263720 | 0.71 | SCN10A (0.46) | SCN9ASCN10ACYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10081617-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3283464-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | SCN9A 2478/4885SCN2A 3026/4885SCN3A 2340/4885 |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | F11, F2, TFPI | SCN9A 2056/4885SCN2A 3652/4885SCN3A 3377/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SCN9A 3960/4885SCN2A 2464/4885SCN3A 1106/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SCN9A 3960/4885SCN2A 2464/4885SCN3A 1106/4885 |
| US-10081617-B2 | Factor XIa inhibitors | F11, F2, TFPI | SCN9A 2056/4885SCN2A 3652/4885SCN3A 3377/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SCN9A 3960/4885SCN2A 2464/4885SCN3A 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.